Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study-Reference-Cited by-同舟云学术

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

Published:2021-04 Issue:4 Volume:61 Page:662-672
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Lipton Richard B.¹^ORCID,Cohen Joshua M.²,Galic Maja³,Seminerio Michael J.⁴,Yeung Paul P.²,Aycardi Ernesto²,Bigal Marcelo E.⁵,Bibeau Kristen²,Buse Dawn C.¹

Affiliation:

1. Department of Neurology Albert Einstein College of Medicine Bronx NY USA

2. Global Medical Affairs Teva Branded Pharmaceutical Products R&D, Inc. West Chester PA USA

3. Global Medical Affairs Teva Pharmaceuticals Europe B.V. Amsterdam The Netherlands

4. North America Medical Affairs Teva Branded Pharmaceutical Products R&D, Inc. West Chester PA USA

5. Research and Development Teva Branded Pharmaceutical Products R&D, Inc. West Chester PA USA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.14097

Reference33 articles.

1. Comorbidity of migraine and depression: Investigating potential etiology and prognosis

2. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers

3. Migraine, quality of life, and depression: A population-based case-control study

4. Depression and anxiety disorders associated with headache frequency. The Nord-Trøndelag Health Study

5. Depression in chronic migraine: severity and clinical features

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversion of chronic to episodic migraine in working age and botulinum toxin‐resistant patients treated with fremanezumab: A real‐life study;Brain and Behavior;2024-07

2. Begleitende depressive Symptome bei Migräne werden gebessert;InFo Neurologie + Psychiatrie;2024-05

3. Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence;Saudi Pharmaceutical Journal;2024-04

4. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response;Pain and Therapy;2024-03-12

5. Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies;Cephalalgia;2024-02